Royce & Associates LP Relay Therapeutics, Inc. Transaction History
Royce & Associates LP
- $10.3 Billion
- Q2 2024
A detailed history of Royce & Associates LP transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 48,381 shares of RLAY stock, worth $316,411. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,381
Previous 14,222
240.18%
Holding current value
$316,411
Previous $118,000
166.95%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RLAY
# of Institutions
183Shares Held
127MCall Options Held
1.7KPut Options Held
18K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$182 Million1.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$76.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$68.9 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY8.45MShares$55.3 Million4.77% of portfolio
-
Bellevue Group Ag Kuesnacht, V86.38MShares$41.7 Million0.7% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $786M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...